BioCentury
ARTICLE | Finance

Angelic patience

How angels have given Proclara time to craft a protein misfolding platform

September 12, 2016 7:00 AM UTC

Proclara Biosciences Inc. says its nearly all-angel investor base is not as rigid with timelines as traditional VCs, which helped buy enough time to figure out how to truncate bacteriophages into more drug-like molecules.

The proceeds from last week's $47 million series E round bring the company's total to $100 million in eight years and could get the company to a Phase Ib data event in Alzheimer's disease late next year or early in 2018. ...